Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study

Journal of Hypertension

Volumn 22, Issue 8, 2004, Pages 1613-1622

  Marre, Michel ^a,v   Puig, Juan Garcia ^b   Kokot, Franciszek ^c   Fernandez, Margarita ^d   Jermendy, György ^e   Opie, Lionel ^f   Moyseev, Valentin ^g   Scheen, André ^h   Ionescu Tirgoviste, Constantin ⁱ   Helena Saldanha, M ^j   Halabe, Aaron ^k   Williams, Bryan ^l   Decio Jr , Mion ^m   Ruiz, Maximino ⁿ   Hermansen, Kjeld ^o   Tuomilehto, Jaakko ^p   Finizola, Bartolomé ^q   Gallois, Yves ^r   Amouyel, Philippe ^s   Ollivier, Jean Pierre ^t   Asmar, Roland ^u   more..

^a Hôpital Bichat   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e Bajcsy Zsilinszky District Hospital   (Hungary)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Therapevticheski korpus   (Russian Federation)

^h CHU SART TILMAN   (Belgium)

ⁱ Clin of Nutr and Metabolic Disease   (ROM)

^j CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^k WOLFSON MEDICAL CENTER   (Israel)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

ⁿ HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^o AARHUS UNIVERSITY HOSPITAL   (Denmark)

^p NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^q Asociacion Cardiovascular Centroccidental Venezuela   (Venezuela)

^r ANGERS UNIVERSITY HOSPITAL   (France)

^s INSTITUT PASTEUR DE LILLE   (France)

^t Hop Militaire du Val de Grace   (France)

^u Institut CardioVasculaire

^v BICHAT HOSPITAL   (France)

more..

Author keywords

Angiotensin converting enzyme inhibitors; Diuretics; Enalapril; Hypertension; Indapamide sustained release; Microalbuminuria; Randomized trial; Type 2 diabetes

Indexed keywords

ALBUMIN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; INSULIN; POTASSIUM;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUSTAINED RELEASE FORMULATION;

EID: 3843080677     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000133733.32125.09     Document Type: Article

References (44)

1. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342:1040-1042.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
3. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985-86; 9:85-95.
4. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
5. Jarrett RJ, Keen H, McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening diabetes and predictors of death. Diab Med 1984; 1:279-283.
6. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41:736-741.
7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study [published erratum appears in Lancet 2000; 356:860] Lancet 2000; 355:253-259.
8. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephrapathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297:1092-1095.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published erratum appears in N Engl J Med 1993; 330:152]. N Engl J Med 1993; 329:1456-1462.
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engt J Med 2001; 345:851-860.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
12. Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993; 306:175-182.
13. American Diabetes Association: Diabetic Nephropathy. Diabetes Care 2003; 6 (suppl 1):S94-S97.
14. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published errata appear in N Engl J Med 2000; 342:748, 1376]. N Engl J Med 2000; 342:145-153.
15. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-E32.
16. Parving HH, Jensen HA, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 15:1190-1192.
17. 7 Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34:655-661.
18. Marre M, Garcia-Puig J, Kokot F, Fernandez M, Germendy G, Opie L, et al. Effect of indapamide SR on microalbuminuria - The NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia), Rationale and protocol for the main trial. J Hypertens 2003; 21 (suppl 1):S19-S24.
19. Singer DE, Samet JH, Coley CM, Nathan DM. Screening for diabetes mellitus. Ann Intern Med 1988; 109:639-649.
20. Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P. Laser immunonephlometry for routine quantification of urinary albumin excretion. Clin Chem 1987; 33:209-213.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
22. Joint National Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda: National Institute of Health, National Heart, Lung and Blood Institute; 1997, p. 73.
23. O'Brien E, Petrie J, Litter W, de Swiet M, Padfield PL, O'Malley K, et al. The British Hypertension Society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special references to ambulatory systems. J Hypertens 1990; 8:607-619.
24. Association for the Advancement of Medical Instrumentation (AAMI). Arlington: American National Standard for Electronic or Automated Sphygmomanometers; 1987.
25. White WB, Berson AS, Robbins C, Jamieson MJ, Prisant LM, Rocce E, et al. National standard for measurement of resting and ambulatory blood pressure with automated Sphygmomanometers. Hypertension 1993; 21:504-509.
26. Poggi L, Mallion JM, Renucci JF, Vaïsse B, de Gaudemaris R, Chanudet X, et al. Mesure ambulatoire non invasive de la pression artérielle. Recommandations du groupe de la mesure de la Société française d'hypertension artérielle. Arch Mal Coeur 1993; 86:1137-1142.
27. Andrejak M, Mallion JM, Asmar R, Chau NG, de Gaudemaris R, Drici M, et al. Mesures ambulatoires de la pression artérielle et essais thérapeutiques. Arch Mal Coeur 1995; 88:1175-1178.
28. Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, et al. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 1994; 24:753-761.
29. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18:1465-1475.
30. Zezulka AV, Gill JS, Dews I, Joy MD, Beevers DG. Comparison of enalapril and bendrofluazide for treatment of systemic hypertension. Am J Cardiol 1987; 59:630-633.
31. Stornello M, Valvo EV, Puglia N, Scapellato L. Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypertens 1988; 6 (suppl 4):S464-S466.
32. Todd PA, Goa KL. Enalapril: a preappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 43:346-381.
33. Ravid M, Lang R, Rachmani R, Lishner M. Long term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-diabetes mellitus. A 7-year follow-up study. Arch Int Med 1996; 156:286-289.
34. Björk S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304:339-343.
35. Nielsen FS, Rossing P, Gall MA, Skett P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43:1108-1112.
36. Nielsen FS, Rossing P, Gall MA, Skatt P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46:1182-1188.
37. UK Prospective Diabetes Study Group. UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317:713-720.
38. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39:1569-1576.
39. Smith HW. The kidney structure and function in health and disease, ch 23. New York: Oxford University Press; 1951, pp. 694-751.
40. The ALLHAT Officers and Coordinators. Major outcomes in high risk hypertensive patients randomised to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 228:2981-2997.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998; 352:837-853.
42. Lievre M, Gueyffier F, Ekbom T, Fagard R, Cutler J, Schron E, et al., for the INDANA Steering Committee. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from a meta-analysis. Diabetes Care 2000; 23 (suppl 2):B65-B71.
43. Joint National Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572.
44. Guidelines Committtee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.